{"filing":{"accession_number":"0001628280-26-038499","cik":"0001178670","ticker":"ALNY","company_name":"ALNYLAM PHARMACEUTICALS, INC.","form":"8-K","filing_date":"2026-05-27","report_date":null,"primary_document":"alny-20260520.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1178670/000162828026038499/alny-20260520.htm"},"events":[{"id":8864,"run_id":7784,"accession_number":"0001628280-26-038499","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Benjamin F. Cravatt, Ph.D. was elected to the Board of Directors effective June 1, 2026, expanding the Board from ten to eleven members and assigned to the Science and Technology Committee. His compensation package includes an annual cash retainer of $75,000 and an initial stock option grant valued at $600,000.","company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":2078,"accession_number":"0001628280-26-038499","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the election of Benjamin F. Cravatt, Ph.D. to the Board of Directors effective June 1, 2026, expanding the Board from ten to eleven members. While the filing also details Dr. Cravatt's compensation package (annual cash retainer of $75,000, initial stock option grant of $600,000 fair value, and eligibility for future annual equity awards), the principal action disclosed is his appointment to the Board and assignment to the Science and Technology Committee. This is a material event affecting the composition of the registrant's governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:40:00.888257+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":8865,"run_id":7784,"accession_number":"0001628280-26-038499","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Alnylam held its Annual Meeting of stockholders on May 27, 2026, with voting results disclosed for three matters: re-election of three Class I directors (Stuart A. Arbuckle, Yvonne L. Greenstreet, and Elliott Sigal), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditors.","company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","filing_date":"2026-05-27","form":"8-K","submitted_at":null,"items":[{"id":2079,"accession_number":"0001628280-26-038499","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the results of Alnylam's Annual Meeting of stockholders held on May 27, 2026, including voting outcomes for three matters: re-election of three Class I directors (Stuart A. Arbuckle, Yvonne L. Greenstreet, and Elliott Sigal), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditors. The filing explicitly states voting tallies (Votes For, Against, Abstentions, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results disclosures under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:40:00.888257+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2078,"accession_number":"0001628280-26-038499","item_number":"5.02","item_title":null,"event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The disclosure centers on the election of Benjamin F. Cravatt, Ph.D. to the Board of Directors effective June 1, 2026, expanding the Board from ten to eleven members. While the filing also details Dr. Cravatt's compensation package (annual cash retainer of $75,000, initial stock option grant of $600,000 fair value, and eligibility for future annual equity awards), the principal action disclosed is his appointment to the Board and assignment to the Science and Technology Committee. This is a material event affecting the composition of the registrant's governance structure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:40:00.888257+00:00","company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","filing_date":"2026-05-27"},{"id":2079,"accession_number":"0001628280-26-038499","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This Item 5.07 disclosure presents the results of Alnylam's Annual Meeting of stockholders held on May 27, 2026, including voting outcomes for three matters: re-election of three Class I directors (Stuart A. Arbuckle, Yvonne L. Greenstreet, and Elliott Sigal), advisory approval of named executive officer compensation, and ratification of PricewaterhouseCoopers LLP as independent auditors. The filing explicitly states voting tallies (Votes For, Against, Abstentions, and Broker Non-Votes) for each proposal, which is the standard format for shareholder vote results disclosures under Item 5.07.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-28T02:40:00.888257+00:00","company_name":"ALNYLAM PHARMACEUTICALS, INC.","ticker":"ALNY","filing_date":"2026-05-27"}]}